Collegium Pharmaceutical, Inc. (COLL)
COLL Stock Price Chart
Explore Collegium Pharmaceutical, Inc. interactive price chart. Choose custom timeframes to analyze COLL price movements and trends.
COLL Company Profile
Discover essential business fundamentals and corporate details for Collegium Pharmaceutical, Inc. (COLL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
7 May 2015
Employees
357.00
Website
https://www.collegiumpharma.comCEO
Vikram Karnani
Description
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
COLL Financial Timeline
Browse a chronological timeline of Collegium Pharmaceutical, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $1.68, while revenue estimate is $199.48m.
Earnings released on 7 May 2026
EPS came in at $1.76 surpassing the estimated $1.52 by +15.79%, while revenue for the quarter reached $193.52m , beating expectations by +4.91%.
Earnings released on 26 Feb 2026
EPS came in at $2.04 falling short of the estimated $2.14 by -4.67%, while revenue for the quarter reached $205.45m , missing expectations by -0.44%.
Earnings released on 6 Nov 2025
EPS came in at $2.25 surpassing the estimated $1.86 by +20.97%, while revenue for the quarter reached $209.36m , beating expectations by +1.55%.
Earnings released on 7 Aug 2025
EPS came in at $1.68 surpassing the estimated $1.62 by +3.70%, while revenue for the quarter reached $188.00m , missing expectations by -1.73%.
Earnings released on 8 May 2025
EPS came in at $1.49 surpassing the estimated $1.43 by +4.20%, while revenue for the quarter reached $177.76m , beating expectations by +2.70%.
Earnings released on 27 Feb 2025
EPS came in at $1.77 surpassing the estimated $1.54 by +14.94%, while revenue for the quarter reached $181.95m , beating expectations by +1.26%.
Earnings released on 7 Nov 2024
EPS came in at $1.61 surpassing the estimated $1.59 by +1.26%, while revenue for the quarter reached $159.30m , missing expectations by -11.25%.
Earnings released on 8 Aug 2024
EPS came in at $1.62 surpassing the estimated $1.49 by +8.72%, while revenue for the quarter reached $145.28m , beating expectations by +0.93%.
Earnings released on 9 May 2024
EPS came in at $1.45 falling short of the estimated $1.47 by -1.36%, while revenue for the quarter reached $144.92m , missing expectations by -1.37%.
Earnings released on 22 Feb 2024
EPS came in at $1.58 surpassing the estimated $1.38 by +14.49%, while revenue for the quarter reached $149.75m , beating expectations by +1.19%.
Earnings released on 7 Nov 2023
EPS came in at $1.34 surpassing the estimated $1.22 by +9.84%, while revenue for the quarter reached $136.71m , missing expectations by -1.31%.
Earnings released on 3 Aug 2023
EPS came in at $1.26 surpassing the estimated $1.22 by +3.28%, while revenue for the quarter reached $135.55m , missing expectations by -2.06%.
Earnings released on 4 May 2023
EPS came in at $1.32 falling short of the estimated $1.33 by -0.75%, while revenue for the quarter reached $144.77m , beating expectations by +4.55%.
Earnings released on 23 Feb 2023
EPS came in at $1.09 matching the estimated $1.09, while revenue for the quarter reached $129.62m , beating expectations by +3.52%.
Earnings released on 3 Nov 2022
EPS came in at $1.10 falling short of the estimated $1.38 by -20.29%, while revenue for the quarter reached $127.01m , beating expectations by +2.12%.
Earnings released on 4 Aug 2022
EPS came in at $0.13 falling short of the estimated $1.44 by -90.97%, while revenue for the quarter reached $123.55m , beating expectations by +1.99%.
Earnings released on 10 May 2022
EPS came in at $0.60 falling short of the estimated $0.90 by -32.96%, while revenue for the quarter reached $83.75m , beating expectations by +6.46%.
Earnings released on 24 Feb 2022
EPS came in at -$0.73 falling short of the estimated $1.04 by -170.19%, while revenue for the quarter reached $27.36m , missing expectations by -66.44%.
Earnings released on 4 Nov 2021
EPS came in at $0.22 falling short of the estimated $0.95 by -76.84%, while revenue for the quarter reached $78.84m , missing expectations by -7.39%.
Earnings released on 5 Aug 2021
EPS came in at $0.27 falling short of the estimated $0.34 by -20.59%, while revenue for the quarter reached $82.94m , missing expectations by -2.16%.
COLL Stock Performance
Access detailed COLL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
